ProCE Banner Activity

AMBER Parts 1C and 1E: Phase I Trial of Cobolimab, an Anti–TIM-3 mAb, Plus Dostarlimab in Advanced Melanoma

Slideset Download
Conference Coverage
In the phase I AMBER trial, the anti–TIM-3 mAb cobolimab combined with dostarlimab showed a manageable safety profile in patients with advanced solid tumors and preliminary antitumor activity in patients with advanced melanoma.

Released: June 20, 2022

Expiration: June 19, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab